STOCK TITAN
  1. Home
  2. Sec-filings
  3. ELVN
  4. [Form 4] Enliven Therapeutics, Inc. Insider Trading Activity

Enliven Therapeutics (ELVN) COO receives major new stock awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Enliven Therapeutics reported new equity awards for Chief Operating Officer Anish Patel. On February 12, 2026, he received a stock option covering 120,000 shares of common stock at an exercise price of $0.00 per share, vesting 25% on February 12, 2027 and the remainder in equal monthly installments thereafter. He also acquired 20,000 restricted stock units, each representing one share of common stock, with 25% vesting on March 1, 2027 and the balance vesting in equal installments each June 1, September 1, December 1, and March 1 thereafter, while he continues as a service provider. In addition, an indirect holding of 215,011 common shares is reported as held by The Patel / Dong Family Trust, for which he serves as trustee.

Positive

  • None.

Negative

  • None.
Insider Patel Anish
Role CHIEF OPERATING OFFICER
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 120,000 $0.00 --
Grant/Award Common Stock 20,000 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 120,000 shares (Direct); Common Stock — 20,000 shares (Direct); Common Stock — 215,011 shares (Indirect, See footnote)
Footnotes (1)
  1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. The shares are held by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee. 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Patel Anish
(Last) (First) (Middle)
C/O ENLIVEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
(Street)
BOULDER CO 80301
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF OPERATING OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/12/2026 A 20,000(1) A $0 20,000(1) D
Common Stock 215,011 I See footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $27.16 02/12/2026 A 120,000 (3) 02/12/2036 Common Stock 120,000 $0 120,000 D
Explanation of Responses:
1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.
2. The shares are held by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee.
3. 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Remarks:
The Reporting Person is no longer deemed an executive officer under Section 16 after February 12, 2026.
/s/ Ben Hohl, by power of attorney 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider equity awards did ELVN COO Anish Patel receive?

Anish Patel received a stock option for 120,000 shares and 20,000 RSUs. Both awards were granted on February 12, 2026, with multi-year vesting schedules tied to his continued service as a provider to Enliven Therapeutics.

How do the new stock options for ELVN COO Anish Patel vest?

The 120,000-share stock option vests over four years. One quarter vests on February 12, 2027, and the remaining three quarters vest in equal monthly installments thereafter, subject to Anish Patel continuing as a service provider to Enliven Therapeutics.

What is the vesting schedule for ELVN COO Anish Patel’s RSUs?

The 20,000 RSUs vest gradually starting March 1, 2027. One quarter vests on that date, with the remaining units vesting in equal portions each June 1, September 1, December 1, and March 1, conditioned on his continued service.

What indirect shareholdings in ELVN are reported for Anish Patel?

An indirect holding of 215,011 common shares is reported. These shares are held by The Patel / Dong Family Trust dated August 24, 2017, with Anish Patel serving as trustee, giving him a trustee role over the position.

Are ELVN COO Anish Patel’s new grants open-market purchases?

No, the Form 4 shows equity awards, not market purchases. The 120,000-share option and 20,000 RSUs were granted at a stated price of $0.00 per share as compensation, subject to the specified vesting conditions and continued service.

How many ELVN options does Anish Patel hold after the new grant?

After the February 12, 2026 grant, he holds 120,000 option shares. This option position reflects the newly awarded Stock Option (right to buy) reported as directly owned, subject to the four-year vesting timeline described in the filing.